Novo Nordisk plans to make bariatric surgery a thing of the past: The key is not one but two drugs
Combinations of at least two different drugs have become an important element of Novo Nordisk's future plans within obesity, fatty liver disease and diabetes. One combination in particular looks set to become a top product, says chief science officer.
BY KEVIN GRØNNEMANN, TRANSLATED BY IDA JACOBSEN
For years, Novo Nordisk has dreamed of developing an obesity drug so effective that no one ever needs to undergo bariatric surgeries that shorten the gut and stomach permanently.
Now, it would seem that the solution is not one drug – but two.
Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.